– Sanofi-aventis Acquires from Ascendis Pharma worldwide rights on Drug-Delivery Technology in Diabetes and Related Disorders – Innovative technology designed for sustained release of peptides and proteins – Paris, France – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Ascendis…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected a Nanobody candidate for development. This is the first development candidate emerging from the strategic alliance which the companies entered into in 2007, and will result in…
– COPENHAGEN, Denmark and PRINCETON, New Jersey - Symphogen A/S announced today that it has received an undisclosed milestone payment related to an antibody therapeutic in development under its ongoing collaboration with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX:…
– Heidelberg, Germany - mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its…
– Utrecht, The Netherlands - Gilde Healthcare Services (Gilde), a growth capital fund specialised in Healthcare Services, has acquired a significant minority stake in elderly care provider Stepping Stones Home & Care (Stepping Stones) of the Netherlands to fund further growth of the…
– IRVINE, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company’s MammaPrint test. Agendia’s contract with Humana expands the…
– Ablynx And Merck Serono Enter Into Second Agreement To Co-Discover And Co-Develop Nanobodies® GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that they have expanded their relationship and entered into a…
– COPENHAGEN, Denmark and Stockholm, Sweden – Symphogen and Swedish Orphan Biovitrum (STO:SOBI) today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to rozrolimupab (Sym001) for the treatment of primary Immune Thrombocytopenia…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced that it has opened recruitment in its first clinical trial centre for an open-label, randomised Phase II study for patients with acquired thrombotic thrombocytopenic purpura (TTP). This Phase II study will be conducted in…
– Freising-Weihenstephan, Germany - Pieris AG announced the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which Pieris will apply its proprietary…
– Copenhagen, Denmark, September 16, 2010 – Ascendis Pharma A/S, a privately held specialty pharmaceutical company, announced that it has initiated a Phase 2 clinical study of ACP-001, a proprietary once-weekly human growth hormone prodrug. The Phase 2 clinical study will be conducted…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces the initiation of two clinical development programmes: APD421 for the prevention and treatment of nausea & vomiting; and APD515 for the treatment…
– Former Idun Management team to expand efforts in liver disease and oncology SAN DIEGO - Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc. Financial terms were not disclosed. Conatus Pharmaceuticals is a privately-held…
– COPENHAGEN, Denmark and PRINCETON, New Jersey - Symphogen A/S announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 7,749,697, titled "Method for linking sequences of interest." The patent broadly covers Symphogen's Symplex™ technology, a novel…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced today that Novartis has obtained licenses to further develop and commercialise Nanobodies against two complex targets. This has triggered a total of €1 million in upfront fees and license payments to Ablynx. The two targets…
– Large retrospective study in more than 800 cases now published in American Journal of Clinical Pathology Heidelberg, Germany – mtm laboratories, a fully integrated cancer diagnostics company with proprietary products marketed globally, today announced the publication of a large study…
– LEIDEN, THE NETHERLANDS and SEATTLE, WA - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical and commercial supply of plasma-based fibrinogen…
– Anti-VEGF PRS-050 is first Anticalin tested in humans Freising-Weihenstephan, Germany - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation…
– Freising-Weihenstephan - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive…
– Study results presented at EFC Congress, Berlin 27-29 May 2010 Heidelberg, Germany - mtm laboratories today announced the results of a study that showed dual staining for p16 and Ki-67 in a single test was capable of identifying the underlying cases with high-grade disease among…
– GHENT, Belgium -Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for the treatment of Alzheimer's disease. This is the first lead candidate emerging from the Alzheimer's disease collaboration…
– US-based Medtech portfolio company FlowCardia Inc acquired by C.R. Bard Utrecht, The Netherlands – Gilde Healthcare Partners, an investor in Healthcare Technologies and Services, announces the sale of its portfolio company FlowCardia, Inc. to C.R. Bard for a total amount of approximately…
– Freising-Weihenstephan, Germany - Pieris AG announced preclinical data for its proprietary PRS-110 Anticalin® compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model. The results provide an indication that an…
– Company demonstrates ability to manufacture for large therapeutic markets COPENHAGEN, Denmark and PRINCETON, New Jersey - Symphogen A/S today announced the publication of data in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al. [epub ahead of print]…
– Waltham, MA—BG Medicine, Inc. announced today that it has entered into an agreement with Inverness Medical Innovations, Inc. (NYSE: IMA)—a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management—for…
– Santaris Pharma A/S selects lead research compound SPC5001 targeting PCSK9 to advance into drug development for the treatment of high cholesterol PCSK9, an important new target, is a protein involved in regulating LDL or “bad” cholesterol in the blood– a major risk factor for coronary…
– HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today it has closed an agreement with Ferrer inCode for the commercialization of Agendia’s FDA-cleared breast cancer recurrence test MammaPrint in Latin America. …
– Copenhagen, Denmark and PRINCETON, New Jersey - Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced today that it has advanced ALX-0171, a new Nanobody®-based therapeutic programme, into pre-clinical development for the treatment of respiratory synctial virus (RSV) infections. ALX-0171 is a Nanobody product which binds…
– HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites. I-SPY 2 is an…
– GHENT, Belgium - Ablynx, the biopharmaceutical company focused on the discovery and development of Nanobodies®, announced that it has successfully completed its Secondary Public Offering (the "SPO" or "Offering") raising €50 million. The offered shares were priced at €7.5 per share.…
– LEIDEN, THE NETHERLANDS and SEATTLE, WA - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps. Promising preliminary data from…
– Waltham, MA—BG Medicine, Inc. today announced that it has entered into an agreement with Abbott Laboratories (NYSE: ABT) to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care’s i-STAT System.…
– Powerful new biomarker combination for cervical cancer screening mtm laboratories, a privately held diagnostics company today announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], announced today that it has been awarded a grant worth €1.2 million by the Flemish agency for Innovation by Science and Technology (IWT). The grant supports Ablynx in accelerating the development of its Nanobody-based programme,…
– Results Published in the American Journal of Clinical Pathology Heidelberg, Germany - mtm laboratories, a privately held diagnostics company, today announced the publication of new research showing that CINtec Histology p16 immunostaining significantly increased the accuracy for…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced today that it has selected a new GPCR targeting development candidate, ALX-0651, an anti-CXCR4 Nanobody which is being developed for hematopoietic stem cell mobilisation. The Company is also releasing new data on pulmonary…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has been successful in the opposition that it had filed in 2007 against the European Patent 1 517 921, which was granted in 2006 to Domantis (now a member of the GlaxoSmithKline group of companies). As a result,…
– Study designed to confirm CROSSER® Catheter routinely navigates through the central lumen of SFA chronic total occlusions Sunnyvale, CA – FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced…
– Waltham, MA — BG Medicine, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range of…
– BG Medicine, Inc., a privately-held developer of biomarker-based in vitro diagnostics, announced the commercial launch in the European Union of a new, CE-marked test for the measurement of galectin-3 in human plasma or serum. Galectin-3 was first shown by researchers at the University…
– Novel mechanism of action resulted in superior anticancer effects vs ERBITUX® and Vectibix® Sym004 advancing into the clinic Results further validate Symphogen’s proprietary discovery platforms to identify potential antibody therapeutics for serious diseases COPENHAGEN, Denmark…
– Appointment will bring substantial deal-making expertise to the company Freising-Weihenstephan, Germany – Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper,…